Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) are a rapidly advancing class of targeted cancer therapies that have gained significant attention in recent years. As of March 2025, the US Food and Drug Administration (FDA) has approved 13 ADCs for the treatment of various cancers, including hematologic malignancies and solid tumors, with many more in the clinical research pipeline.

To optimize patient outcomes, oncology providers and multidisciplinary care team members must stay up to date on emerging clinical trial data, patient selection criteria, toxicity management, and evolving treatment strategies. As understanding of ADCs continues to expand, their impact on the treatment of various cancer types is expected to grow.